Oral PD-L1 Inhibitor

It has been our longstanding strategy to combine agents that reduce and suppress the HBV immune tolerizing antigen, HBsAg, with agents that can further reawaken the immune system.


Highly functional HBV-specific T cells within our immune system are believed to be required for long-term HBV viral control. However, HBV-specific T cells become functionally defective, and reduced in number during chronic HBV infection. One approach to boost HBV-specific T cells is to block the PD-1/PD-L1 protein-protein interaction that is one of the causes of T cell immune disfunction.

Through our comprehensive research, we have identified a class of small molecule oral PD-L1 inhibitors that we believe will allow for controlled checkpoint blockade, enable oral dosing and mitigate systemic safety issues typically seen with checkpoint antibody therapies. We have commenced IND-enabling studies with an oral PD-L1 inhibitor that could potentially be an important part of a combination therapy for the treatment of HBV.